RT Journal Article
SR Electronic
T1 Differences and similarities in diagnostic methods and treatments for Coronavirus disease 2019 (COVID-19): a scoping review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.30.20222950
DO 10.1101/2020.10.30.20222950
A1 Scholze, Alessandro Rolim
A1 Melo, Emiliana Cristina
A1 Major, Carina Bortolato
A1 Cruz, Carolina Fordellone Rosa
A1 de Souza Alcântara, Léia Regina
A1 Dalcol, Camila
A1 Ferreira Seiva, Fábio Rodrigues
A1 de Fátima Mantovani, Maria
A1 Mattei, Ângela Tais
A1 Silveira, Henrique Spaulonci
A1 de Almeida Chuffa, Luiz Gustavo
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.30.20222950.abstract
AB Aims We investigate a range of studies related to COVID-19 with focus on scientific evidence reporting the main diagnosis and treatments of the disease.Main Methods Scoping review conducted in the databases, MEDLINE, Cochrane, Embase, LILACS, Scopus, and Web of Science, and the gray Google Scholar literature, until May 2020. We follow PRISMA-SCR and the recommendations of the Joanna Briggs Institute. The identified studies were independently selected by peers. The qualitative data extracted were synthesized and organized into categories, and the quantitative data were generated through descriptive and inferential statistics.Key-findings 6060 articles were identified, of which 30 were included in this review. The publications are predominantly from China (n=22, 73.3%), and with a type of cross-sectional study (n=12, 40.0%), followed by a cohort (n=7, 23.0%). Among them, 16 studies addressed the diagnosis, and computed tomography was considered as non-invasive complementary method for detecting and evaluating the progression of COVID-19. Laboratory tests have been used to detect enzymatic or viral activities, and to monitor the inflammation associated with COVID-19. 14 studies included different therapeutic associations, such as Lopinavir/Ritonavir (LPV/r) and Arbidol, Hydroxychloroquine, Azithromycin, Tocilizumab and Remdesivir, and Corticosteroids/Plasminogen.Significance The evidence related to diagnostic methods are clear, and include tomography and laboratory tests. Medicinal or associated medications for the treatment of COVID-19, although showing a reduction in signs and COVID-19-related symptoms, can cause adverse effects of mild or severe intensity depending on viral load and inflammatory activity. Additional studies should be performed to identify the most reliable treatment for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work is a scoping review of the literature. Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and materials are fully available without restriction